Current indinavir users were stratified by whether they received indinavir alone or boosted with ritonavir. The indinavir groups had respectively 15 and 24% higher levels of fibrinogen compared to those not taking a PI (both P < 0.0001, Fig. 2). Furthermore, median fibrinogen levels were 8% higher in patients currently taking indinavir boosted with ritonavir (422; 95% CI, 390–475) compared with those taking only indinavir (392; 95% CI, 357–415; P = 0.049).
In other analyses, median fibrinogen levels were also 12% higher in patients taking lopinavir/ritonavir (382; 95% CI, 364–404) compared with those not on a PI (P < 0.0001). Likewise, all other PIs (amprenavir, nelfinavir, and saquinavir) were also associated with higher fibrinogen levels (ranging from 7 to 14%).
Median fibrinogen levels (Fig. 2) were nearly 9% lower in those HIV-infected patients currently using of any of the NNRTIs (340; 95% CI, 323–351) compared with those not using an NNRTI (372; 95% CI, 364–381, P < 0.0001). Median fibrinogen levels were significantly lower among HIV-infected patients on either the NNRTI nevirapine (318; 95% CI, 306–341) or efavirenz (345; 95% CI, 330–369) compared to those not taking an NNRTI (P < 0.0001 and P = 0.0002, respectively); these associations persisted after multivariable adjustment.
We compared median fibrinogen levels in HIV-infected patients who were on PIs exclusive of NNRTIs, on NNRTIs exclusive of PIs, or on both a PI and NNRTI to levels in controls (Fig. 3). Median fibrinogen levels (mg/dl) in HIV-infected patients on PIs but not NNRTIs (372; 95% CI, 363–385) were 11% higher than controls (335; 95% CI, 325 to 345; P < .0001). In contrast, median fibrinogen levels in HIV-infected patients on NNRTIs but not PIs (303; 95% CI, 289 to 342) were almost 10% lower than controls (P = 0.009). Furthermore, median fibrinogen levels in HIV-infected patients taking PIs and NNRTIs together (342; 95% CI, 319–387) were similar to controls (P = 0.16). Among HIV-infected patients, the levels of fibrinogen in both PI-using groups (PI without NNRTI; PI with NNRTI) were statistically significantly higher than those of the NNRTI without PI group (P < 0.0001 and P = 0.003, respectively). Moreover, the group taking PI with an NNRTI had 8% lower median fibrinogen levels than the PI without NNRTI group, but this did not reach statistical significance (P = 0.094).
Multivariable associations with fibrinogen
Factors independently associated with higher fibrinogen levels in HIV-infected patients included age, African-American race, VAT, total SAT, smoking, and current HIV viral load, whereas current CD4 cell count and alcohol use were associated with lower fibrinogen levels (data not shown). After adjustment for these factors, we observed strong associations with specific antiretroviral agents (Table 2) consistent with the univariate findings. Current use of the PIs indinavir and ritonavir were associated with higher fibrinogen levels (both P < 0.0001). Current use of the NNRTIs nevirapine (P = 0.001) and efavirenz (P = 0.049) were associated with lower fibrinogen levels. The associations of these antiretroviral drugs with fibrinogen levels persisted regardless of how adipose tissue was modeled. The magnitude of antiretroviral associations and their statistical significance changed very little after adjustment for high-density lipoprotein, low-density lipoprotein, triglycerides, insulin resistance and blood pressure.
The relationship between CRP and fibrinogen, another marker of inflammation, was also evaluated. After multivariable adjustment, CRP was positively and strongly associated (P < 0.0001) with fibrinogen in both HIV-infected patients and controls (7.2 and 6.4% per doubling of CRP, respectively). The associations of the PI and NNRTI drugs with fibrinogen levels were found to be independent of CRP, as the magnitude of the PI and NNRTI associations changed little after adjusting for CRP (Table 2).
After adjusting for adipose tissue volume, which is known to be associated with fibrinogen levels, we found that type of antiretroviral therapy was specifically associated with fibrinogen levels. Use of PIs as a group was associated with elevated fibrinogen levels. Patients on PIs had 11% higher fibrinogen levels compared with those not on PIs. Koppel et al. reported a similar increase when PI-treated patients were compared with therapy-naive patients . The PI-associated increase in fibrinogen levels was independent of adipose tissue volumes, triglyceride levels, insulin resistance, inflammation, and lifestyle factors.
Unlike previous findings of PI-induced metabolic disturbances which have been observed with some, but not all, PI drugs [20–26], elevation of fibrinogen levels here is seen with all PIs studied, suggesting a class effect. Although we were not able to assess the association of more recently introduced PI drugs, we did find an association of the commonly used lopinavir/ritonavir combination and of ritonavir at boosting doses with higher fibrinogen levels. Most current PI regimens utilize ritonavir boosting.
The association between PIs and elevated fibrinogen levels may contribute to the risk of atherosclerosis. The Framingham study found that each SD increase in fibrinogen level (56 mg/dl) is associated with a 20% independent increment of risk for cardiovascular disease . Although it may not be possible to directly apply the Framingham cardiovascular risk assessment to our study population, the Framingham data suggest that in our study, patients on PIs potentially have a 14% increased risk (39 mg/dl) for cardiovascular disease compared to patients not on PIs. A similar magnitude of disease risk for PI was reported in the DAD study  and by Kwong et al.. Thus, elevation in fibrinogen levels may be a unifying mechanism by which PIs as a class accelerate atherosclerosis.
Fibrinogen levels were also independently associated with CRP, another cardiovascular risk factor that is also associated with acute inflammation. The lack of an association of PIs and NNRTIs with CRP levels  and the finding that adding CRP to the multivariable analysis has virtually no effect on the association of PI with fibrinogen levels suggests that acute inflammation is not a central mechanism by which PI drugs are associated with elevated fibrinogen levels and atherosclerosis. The independent associations of PIs and CRP with fibrinogen levels, suggests that PIs may directly alter fibrinogen levels. It is possible that PIs and NNRTIs are instead more closely associated with regulation of the coagulation pathway itself. Traditional cardiovascular risk factor predictions do not take into consideration these potential effects of antiviral therapy on atherosclerosis.
In multivariable regression analysis, indinavir and ritonavir were the PIs most strongly associated with fibrinogen levels. Indinavir and ritonavir have also been shown to induce insulin resistance, and ritonavir induces hypertriglyceridemia [21–23,26,27]. The combination of elevated fibrinogen levels and insulin resistance or hypertriglyceridemia may confer an even higher risk of atherosclerosis than individual disorder of metabolism alone. PIs that do not induce these metabolic changes were, however, also associated with higher fibrinogen levels. Prospective studies comparing individual PI therapies and cardiovascular morbidity and mortality are required to assess the risk of cardiovascular disease with indinavir and ritonavir therapy compared with other PI therapy.
Ritonavir-boosting of indinavir was associated with higher fibrinogen levels than indinavir or low-dose ritonavir. The patients on boosted indinavir regimens had the highest levels of fibrinogen in our study. Possible mechanisms include an additive effect of ritonavir itself on fibrinogen levels and/or a consequence of increasing the concentration of indinavir. The observation that high-dose ritonavir was associated with higher levels of fibrinogen than lower dose ritonavir, albeit not statistically significant (P = 0.30) supports the concept that total levels of PIs may be important in these effects. Further studies are necessary to assess the effects of individual PI dosage and ritonavir boosting on fibrinogen levels, as most PI regimens in common use at this time employ ritonavir boosting.
In contrast to PIs, NNRTIs were associated with lower fibrinogen levels. Patients taking nevirapine and to a lesser extent efavirenz had lower fibrinogen levels compared to patients not on NNRTIs. Interestingly, levels of fibrinogen with NNRTI therapy were also lower than those levels observed in healthy normal controls. The magnitude of the NNRTI effects changed very little after adjustment for lipids, including high-density lipoprotein levels. Koppel et al. studied HIV-infected patients before the common use of NNRTI . Although they found no decrease in fibrinogen levels in those who switched from PI to NNRTI, the numbers switching were very small (n = 23). It is possible that by lowering fibrinogen levels, NNRTIs confer a protective effect on cardiovascular events in addition to that predicted from their increase in high-density lipoprotein, but further prospective studies of NNRTIs and measures of cardiovascular outcomes are required.
As PIs have been commonly taken in combination with NNRTIs in the past, we examined the relationship between PIs, NNRTIs, and fibrinogen levels. Patients on both NNRTIs and PIs had fibrinogen levels that were intermediate between those levels in patients on PIs alone and NNRTIs alone and comparable to fibrinogen levels in healthy controls. The combined effect of PI and NNRTI therapy on fibrinogen levels strongly suggests a direct drug effect of both therapies.
The multivariable analysis found associations of higher HIV viral load and lower CD4 cell count with higher fibrinogen levels (data not shown). Unlike PIs and NNRTIs, HIV infection is also associated with elevated CRP levels, and thus elevated CRP and fibrinogen levels may be a reflection of the underlying inflammatory state due to HIV disease. It should be noted that the effects of PI and NNRTI persist after adjusting for these factors associated with HIV itself.
Several limitations of this study should be noted. Given the cross-sectional design of the present study, we are unable to prove causality between antiretroviral therapy and alterations in fibrinogen levels. Prospective studies are required to determine the relationship between PIs, NNRTIs, and fibrinogen levels, and relationships to cardiovascular disease events. The present study could not assess the effects of more recently introduced PI drugs. The FRAM study is ongoing, and future analysis is planned of the association of newer PI and other antiretroviral therapies with fibrinogen levels. Additional studies are clearly needed to evaluate the relationship between markers of cardiovascular disease risk in HIV infection, antiretroviral therapy, and cardiovascular morbidity and mortality.
In summary, PIs as a class are associated with higher levels of fibrinogen levels, which may contribute to an increased risk of atherosclerosis in HIV-infected patients. Ritonavir boosting may lead to higher levels of fibrinogen compared to un-boosted PIs. In contrast, NNRTIs are associated with lower fibrinogen levels. Fibrinogen levels in those patients on NNRTIs combined with PIs are similar to those observed in healthy controls. The antiretroviral drug effects appear to be independent of inflammation. Prospective studies are needed to determine the causal relationship between antiretroviral therapy and fibrinogen levels as well as their cardiovascular disease consequences.
Sponsorship: the study was supported by NIH grants RO1- DK57508, HL74814, HL53359, and HL77499 and NIH GCRC grants M01- RR00036, RR00051, RR00052, RR00054, RR00083, RR00636, and RR00865.
The funding agency had no role in the collection or analysis of the data. C.G. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. C.G. received research grants during the time of the study from outside affiliations with Serono Laboratories, Theratechnologies, and EMD Biosciences.
Sites and investigators
University Hospitals of Cleveland (Barbara Gripshover, MD); Tufts University (Abby Shevitz, MD and Christine Wanke, MD); Stanford University (Andrew Zolopa, MD and Lisa Gooze, MD); University of Alabama at Birmingham (Michael Saag, MD and Barbara Smith, PhD); John Hopkins University (Joseph Cofrancesco, MD and Adrian Dobs, MD); University of Colorado Heath Sciences Center (Constance Benson, MD and Lisa Kosmiski, MD); University of North Carolina at Chapel Hill (Charles van der Horst, MD); University of California at San Diego (W. Christopher Mathews, MD and Daniel Lee, MD); Washington University (William Powderly, MD and Kevin Yarasheski, MD); VA Medical Center, Atlanta (David Rimland, MD); University of California at Los Angeles (Judith Currier, MD and Matthew Leibowitz, MD); VA Medical Center, New York (Michael Simberkoff, MD and Juan Bandres, MD); VA Medical Center, Washington DC (Cynthia Gibert, MD and Fred Gordin, MD); St Luke's-Roosevelt Hospital Center (Donald Kotler, MD and Ellen Engelson, PhD); University of California at San Francisco (Morris Schambelan, MD and Kathleen Mulligan, MD, PhD); Indiana University (Michael Dube, MD); Kaiser Permanente, Oakland (Stephen Sidney, MD); University of Alabama at Birmingham (Cora E. Lewis, MD).
Data coordinating center
University of Alabama, Birmingham (O. Dale Williams, PhD, Heather McCreath, PhD, Charles Katholi, PhD, George Howard, PhD, Tekeda Ferguson, and Anthony Goudie)
Image reading center
St Luke's-Roosevelt Hospital Center: (Steven Heymsfield, MD, Jack Wang, MS and Mark Punyanitya).
Office of the principal investigator
University of California, San Francisco, Veterans Affairs Medical Center and the Northern California Institute for Research and Development: (Carl Grunfeld, MD, PhD; Phyllis Tien, MD; Peter Bacchetti, PhD; Dennis Osmond, PhD; Andrew Avins, MD; Michael Shlipak, MD; Rebecca Scherzer, PhD; Mae Pang, RN, MSN; Heather Southwell, MS, RD; Erin Madden, MPH; and Yong Kyoo Chang).
1. Currier JS, Taylor A, Boyd F, Dezii CM, Kkawabata H, Burtcel B, et al
. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506–512.
2. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471–477.
3. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al
. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723–1735.
4. Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, et al
. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20:1941–1950.
5. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 40:1215–1220.
6. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10:435–441.
7. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al
. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799–1809.
8. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:441–449.
9. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al
. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63–F70.
10. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al
. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121–131.
11. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr
12. Alessi MC, Lijnen HR, Bastelica D, Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2003; 33:290–297.
13. Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy nonobese men. Metabolism 2004; 53:984–988.
14. Piche ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005; 96:92–97.
15. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al
. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105–1116.
16. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860–869.
17. Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, Pi-Sunyer FX, Heymsfield SB. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 1998; 275:E249–E258.
18. Hastie T, Tibshirani RJ. Generalized additive models. New York: Chapman and Hall; 1990.
19. Efron B, Tibshirani R. An introduction to the boostrap. London: Chapman and Hall; 1993.
20. Lee G, Lo JC, Aweeka F, Schwarz J-M, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir/ritonavir acutely inhibits insulin-mediated glucose disposal in healthy normal volunteers. Clin Infect Dis 2006; 43:658–660.
21. Lee G, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007; 21:2183–2190.
22. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al
. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641–649.
23. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11–F18.
24. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al
. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137–2144.
25. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813–1821.
26. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al
. Effect of ritonavir on lipids and postheparin lipase activities in normal subjects. AIDS 2000; 14:51–57.
27. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258:1183–1186.
28. Reingold JS, Wanke C, Kotler DP, Lewis CE, Tracy R, Heymsfield S, Tien PC, Bacchetti P, Scherzer R, Grunfeld C, Shlipak MG. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The FRAM Study.JAIDS
2008 in press.
Keywords:© 2008 Lippincott Williams & Wilkins, Inc.
fibrinogen; HIV; nonnucleoside reverse transcriptase inhibitors; protease inhibitors